Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

APOLLO-BC: Advanced Perfused platform for Breast Cancer therapy-response prediction

Objective

The limited ability of preclinical models to predict clinical responses remains a major barrier in oncology drug development. Current systems used for cancer drug evaluation, including conventional 2D cultures and advanced 3D models such as patient-derived organoids (PDOs), fail to control key tumour microenvironment (TME) parameters that influence drug penetration, adaptive resistance, and therapeutic response, potentially limiting predictive accuracy. Consequently, a gap persists between preclinical efficacy and clinical response, highlighting the need for ex vivo systems with improved predictive performance. Breast cancer provides a clinically relevant setting to address this challenge. Subtypes such as TNBC and HER2-positive disease show substantial variability in response to approved therapies, creating a need for improved methods to prioritise treatment options. APOLLO-BC tests whether controlling key tumour microenvironment parameters, specifically perfusion and mechanical stiffness, improves the predictive accuracy of therapy-response ranking compared with PDO systems. The project will generate the first controlled direct comparative validation of a perfused, stiffness-controlled tumour model against conventional PDO workflows using matched patient-derived samples. A microfluidic platform integrating bioprinted 3D tumour constructs and real-time environmental monitoring will be standardised, followed by generation of matched TNBC and HER2+ models and a benchmarking study across ≥40 patients, each tested with ≥6 approved therapeutic regimens. Reproducibility and predictive concordance with retrospective clinical outcomes will be quantitatively compared with PDO workflows.
By generating rigorous comparative evidence, APOLLO-BC will determine whether microenvironmental engineering improves predictive drug-response assessment in breast cancer models, establishing a validated framework for next-generation functional oncology platforms.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2026-POC

See all projects funded under this call

Host institution

FACULDADE DE CIENCIAS E TECNOLOGIADA UNIVERSIDADE NOVA DE LISBOA
Net EU contribution
€ 150 000,00
Address
QUINTA DA TORRE
2829 516 Caparica
Portugal
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)